New study shows 94% of tardive dyskinesia patients on INGREZZA achieve remission or meaningful symptom improvement

A 48-week analysis of the KINECT 4 trial reveals that 94% of adults with tardive dyskinesia treated with INGREZZA either reached symptomatic remission or had a clinically meaningful reduction in involuntary movements. The drug is unique among VMAT2 inhibitors for showing clinical remission in trials and having approved dosing for patients with liver impairment, a common risk factor in this population. These findings support INGREZZA's broad therapeutic potential for improving quality of life in patients with tardive dyskinesia. Additional data from a large Medicare claims study highlight the importance of considering hepatic risk factors in treatment decisions.